{
  "report_rows": [
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$9.54B vs. cons $9.43B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$5.70 vs. cons $5.62",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 non-GAAP operating margin",
      "prediction": "IN-LINE",
      "answer": "pred ~45.2% vs. cons 45.3%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 total revenue guidance midpoint",
      "prediction": "BETTER",
      "answer": "guide ~$38.0B vs. cons $37.81B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP EPS guidance midpoint",
      "prediction": "BETTER",
      "answer": "guide ~$22.55 vs. cons $22.37 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP operating margin guidance midpoint",
      "prediction": "UNCHANGED",
      "answer": "guide ~45.5% vs. cons 45.5% (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.3,
  "day5_path": "FADE",
  "day5_rationale": "Initial upside from Q2 non-GAAP EPS of ~$5.70 vs. $5.62 consensus should fade partially because FY2026 EPS guidance of ~$22.55 vs. $22.37 consensus absorbs much of the quarterly beat, leaving limited out-period estimate revisions amid denosumab erosion, margin pressure, and cybersecurity uncertainty.",
  "day5_confidence": "MEDIUM"
}